Renal dysfunction in patients with myocardial infarction concurrent with type 2 diabetes mellitus


Carbohydrate metabolic disturbances are an independent risk factor for not only the development, but also poor course of cardiovascular diseases, particularly those concurrent with renal dysfunction (RD). This factor acquires particular relevance due to the fact that the incidence of type 2 diabetes mellitus significantly continues to rise worldwide. The review considers the main mechanisms and common components of the pathogenesis of RD, as well as the constituents forming its basis in the presence of carbohydrate metabolic disturbances. Moreover, it highlights the timely detection of RD, a search for new biomarkers of prognostic value for cardiovascular events, and the early diagnosis of RD. The review unveils the present view of optimal diagnostic and management tactics for patients with myocardial infarction concurrent with background diseases.


  1. Puska P., Norrving B. Death and disability due to CVDs. In: Mendis S. Global atlas on cardiovascular disease prevention and control. World Health Organization, Geneva: Hashette Publisers 2011: 2-13.
  2. Иоселианин Д.Г., Сельцовский А.П. Раннее поэтапное восстановление нарушенного кровоснабжения сердца и улучшение ближайшего и среднеотдаленного прогноза у больных острым инфарктом миокарда (клинико-патофизиологические и фармакологические аспекты). М: Колор Ит Студио 2009.
  3. Zoungas S., Woodward M., Сhalmers J. et al. ADVANCE Collaborative Group. Association of HbA1clevels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012; 55 (3): 636-643.
  4. Wild S., Roglic G., Green A. et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
  5. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87 (1): 4-14.
  6. Grundy S.M., Hansen B., Smith S.C. et al. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-556.
  7. Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic Med 2003; 9: 693-702.
  8. Kahn R., King H., Lernmark A. et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow up report on the diagnosis of diabetes mellitus. Diabetes Care 2004; 26: 3160-3177.
  9. Perk J., Gohlke H., Graham I. et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012; 33: 1635-1701.
  10. Zhang Q.L., Rothenbacher D. Prevalence of chronic kidney disease inpopulation-based studies: systematic review. BMC Public Health 2008; 8: 117-130.
  11. Nahas M. The global challenge of chronic kidney disease. Kidney Int 2005; 68: 2918-2929.
  12. Barsoum R.S. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 997-999.
  13. Eggers P.W. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens 2011; 20: 241-245.
  14. Ritz E., Bakris G. World Kidney Day Organising Committee. World Kidney Day: hypertension and chronic kidney disease. Lancet 2009; 373: 1157-1158.
  15. Atkins R.C., Zimmet P. ISN-IFKF World Kidney Day Steering Committee. Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol 2010; 6: 134-136.
  16. Groop P.H., Thomas M.C., Moran J.L. et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58 (7): 1651-1658.
  17. Levey A.S., Stevens L.A., Schmid C.H. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
  18. Culleton B.F., Larson M.G., Wilson P.W. Cardiovascular disease and mortality in a community based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219.
  19. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-1305.
  20. Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
  21. Peterson J.L., Harrington R.A. Revascularization of coronary atherosclerosis in patients with diabetes mellitus. There is more to it than meets the image intensifier. Am Heart J 2005; 149: 190-193.
  22. Sowers J.R., Whaley-Connell A., Hayden M.R. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011; 1 (1): 5-12.
  23. Wuerzner G., Pruijm M., Maillard M. et al. Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am J Kidney Dis 2010; 56: 303-312.
  24. Santopinto J.J., Fox K.A., Goldberg R.J. et al. on behalf of the GRACE Investigators: Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the global registry of acute coronary events (GRACE). Heart 2003; 89: 1003-1008.
  25. Chertow G.M., Fan D., McCulloch C.E. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
  26. Каретникова В.Н, Зыков М.В, Кашталап В.В. и др. Значение почечной дисфункции для госпитального прогноза больных инфарктом миокарда с подъемом сегмента ST. Сердце 2013; 5: 284-289.
  27. Rashidi A., Sehgal A.R., Rahman M. et al. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008; 102: 1668-1673.
  28. Reaven G.M. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011; 95: 875-892.
  29. Shestakova M., Shamkhalova M., Sitkin I. et al. Renal interstitial fibrosis factors in type 2 diabetics with renal artery stenosis. Diabetologia 2009; 52 (1): 426-439.
  30. Adams K.F. Pathophysiologic role of renin-angiotensinaldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm 2004; 61 (2): 4-13.
  31. Ferrario C.M., Strawn W.B. Role of the renin-angiotensin aldosterone system and proinflammatory mediators in thecardiovascular disease. Am J Cardiol 2006; 98 (1): 121-128.
  32. McCullough P.A., Jurkovitz C.T., Pergola P.E. et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167: 1122-1129.
  33. Virtanen J.K., Voutilainen S., Alfthan G. Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factors (KIHD) Study. J Intl Med 2005; 257: 255-262.
  34. Clarke R., Derrick A., Parish S. et al. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-2022.
  35. Schmidt-Ott K.M., Mori K., Kalandadze A. et al. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens 2006; 15 (4): 442-449.
  36. Tasanarong A., Hutayanon P., Maric C. et al. Urinary Neutrophil Gelatinase-Associated Lipocalin predicts the severity of contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures Nephrology 2013; 14: 1471-2369.
  37. MacIsaac R.J., Tsalamandris C., Thomas M.C. et al. The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med 2007; 24: 443-448.
  38. Cepeda J., Tranche S. Cystatin C and Cardiovascular Risk in the General Population Rev Esp Cardiol 2010; 63: 415-422.
  39. Donahue R.P., Stranges S., Rejman K. et al. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care 2007; 30: 1724-1729.
  40. James M.T., Hemmelgarn B.R., Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
  41. Meguid E.l., Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340.
  42. Gaede P., Lund-Andersen H., Parving H.H. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
  43. Zoungas S., de Galan B.E., Ninomiya T. et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type diabetes: new results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
  44. Ruggenenti P., Fassi A., Ilieva A.P. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
  45. Кобалова Ж.Д., Виллевальде С.В., Моисеев В.С. и др. Сердечно-сосудистые заболевания и функциональное состояние почек. Рос кардиол журн 2013; 4: 33-47.
  46. Grundy S.M., Hansen B., Smith S.C. et al. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-556.
  47. Szummer K., Lundman P., Jacobson S.H. et al. Influence of renal function on the effects of early revascularization in non-ST elevation myocardial infarction: Data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120: 851-858.
  48. Heyman S.N., Rosenberg C., Rosen S. Regional alteration in renal hemodinamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005; 20: 6-11.
  49. Neumayer H.H., Junge W., Kufner A., Wening A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 2003; 4: 103-106.
  50. Dangas G., Iakovou I., Nikolsky E. et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19.
  51. Marenzi G., Lauri G., Assanelli E. et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44:1780-1785.
  52. Roghi A., Savonitto S., Cavallini C. et al. Atherosclerosis, Thrombosis and Vascular Biology Study Group and the Italian Society for Invasive Cardiology Investigators: Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med 2008; 9: 375-381.
  53. Herzog H., Littrell K., Arko C. et al. Clinical Characteristics of Dialysis Patients With Acute Myocardial Infarction in the United States. A Collaborative Project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116: 1465-1472.



Abstract - 118


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Evseeva M.V., Karetnikova V.N., Barbarash O.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies